Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strange how the bid and ask are on it this weekend. Hate it that TDAmeritrade does not allow a person to put an order in unless it is exactly to the cent. For example, I can not put an order in at Friday's closing price of .0913 it would have to be .09 or .10!
Medivolve Announces Q3 2021 Results - Reaches Record Levels of Revenue
2021-11-15 18:24 ET - News Release
Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021. Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021. TORONTO, Nov. 15, 2021 /PRNewswire/ - Medivolve Inc. ("Medivolve" or the "Company") (NEO: MEDV)(OTC: COPRF)(FRA: 4NC), a healthcare technology company that seeks to reinvent the US healthcare system by leveraging a bespoke telehealth platform, clinical diagnostic network, and data driven AI to improve patient care, today announced financial results for the third quarter ended September 30, 2021.
They will be holding a webinar on Feb 22 to discuss Medivolve and Collection Sites telehealth strategy more broadly. They also announced Tim Shelburn, President of collection sites to be replaced. Interesting news all around, been in since 0.18 and believe in this company
With new accounts, we’ll probably both be called bots, but I was in last month at 0.55. Positive it was going to make serious gains. When it flatlined, I thought that was weird. Earnings were released, and they made 7m in spite of a rapid expansion. Only 1m more than December. I went searching for even more info and came across a stock board like this. One user kept saying “read the reviews.” Everyone else was ripping him apart, saying he was a troll, a bot, a bashed, etc...
But it made me curious, so I went looking for reviews. On Yelp, Facebook, BB, there is not a SINGLE POSITIVE review for testbeforeyougo.com. They are all bad. No one at the kiosks, inappropriate hygiene protocols, forcing test upsells, no test results after weeks, INCORRECT results (yikes!)...
If you scroll down, there’s a comment from another person on here who had a similar experience using them. She chalked it up to new business bumps. But it looks like this might be par for the course. I’m not saying it’s a scam. But it was enough for me, combined with the lacklustre M-o-M earnings and much slower than expected rollout that made me pull my investment at a loss.
I hope my suspicions are incorrect. They’ve got some really awesome, optimistic investors, and I want to see them do well.
As far as steering clear, that is 100% your call. No startup hit the ground running without a few hiccups.
Actually, I'm not sure about the antibody test. It said we were negative, but I could swear I had Covid-19 late last January and my fiance had the same symptoms in mid March. Neither of us got tested at the time since tests were still not generally available. The literature indicates that the antibodies quickly go down once your over the virus but that the immunity may still persist in the T cells. I'm thinking that perhaps because it had been so long since we were sick that the test couldn't pick up any antibodies but that that didn't really prove we hadn't had Covid. I was hoping that the lab results might give us better information but we never received them.
Just before Thanksgiving, my fiance and I went to a test site here in Milpitas, CA and received an antibody fingerprick blood test. We were told on the spot that we didn't have antibodies, however, the woman who did the test said she wasn't supposed to reveal that and we would get a formal email from the test center within 24 hours. I received an email within hours asking me to confirm my email address. My fiance didn't receive anything. Neither of us ever got an official test result.
I'm chalking it up to startup issues. The kiosk also offered two Covid-19 blood tests but they only had one of them available at the time of our visit. On the plus side, we confirmed that at least some of the kiosks were deployed.
If the vaccines become available over the next couple months, I expect that the need for the Covid-19 tests will quickly decline. However, the company can still make millions in the meantime. I just hope they have a plan that takes them beyond 2021.
Thats a long way off, this story is really about the tester. To this day we don't have one out there, despite all the talk about testers. I dont't know about down there, but up here we still don't have a radid test. The second part to the story is taking pressure off the hospitals. Theres two stages to Covid, this will help with the first stage of course. If their game plan comes through this can run. If they have a tester that works, then look out. The CEO ran Teva Canada division for a while.
COPRF/ QSC.N this little covid play is gonna fly. Big bio CEO in here from Toronto. Covid test stations all over the US with a 50% take on the distribution of a rapid test approved for fast track by the FDA. These Covid test cubes will be everywhere; malls, plaza's, shopping centers.
Unique COVID-19 testing model verified with strong demand from initial 20 sites: 7-Day average of 73 tests/day per site and $95 per test. Investor webinar scheduled December 10th (1 pm ET).
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce strong initial test sales at its wholly owned subsidiary, Collection Sites, LLC.
Highlights Include:
- Surging test sales amid recent Collection Sites media coverage and increasing COVID-19 cases across the United States. Demand for Collection Sites unique value-proposition of convenient and effective COVID-19 testing verifies operational model;
- Initial 20 sites showing strong tests sales with 7-day rolling average of 73 tests per day per site and average test price exceeding $95 per test;
- Rapid antigen tests’ point-of-care capabilities allows for increased testing capacity, with one Collection Site recording sales of 186 tests in a single day;
- The launch of 25 additional collection sites in hand-picked, high traffic locations across the United States, with installation beginning this week;
- The leasing of new portable trailers from WillScot, drastically reducing upfront capital requirements and providing refuge for customers in the coming winter season;
- Continued engagement with retailers, with up to 743 contracted collection sites across the United States with partners like Simon’s Property Group, Brookfield Properties, Sandor, among others;
- QuestCap is hosting a Corporate Update webinar on Thursday, December 10th at 1 pm ET for investors (register here).
“As COVID-19 cases continue to rise across the United States, Collection Sites testing centres are seeing increased demand from both consumers as well as businesses eager to offer COVID-19 testing to employees and customers,” says Mr. Doug Sommerville, CEO of QuestCap, Inc. “Having now refined our operational model with the launch of the first 20 cubes, we are now ready to expand our network and get convenient and effective COVID-19 test results to everyday Americans so we can flatten the curve.”
Collection Sites Expands Test Offerings and Footprint
Starting on November 16th, COVID-19 rapid antigen tests were distributed to the operating Collections Sites. These tests retail for US$99 per test, and are the most sought after by customers, with strong initial demand in the initial days. These tests also provide Collection Sites with the highest profit margin per test, strengthening profitability of each testing cube. The collection sites have an estimated capacity of up to 150 tests per day when fully staffed, where they operate 7 days a week. However, due to the point-of-Care capabilities of the rapid antigen tests, to date one Collection Site recorded sales of 186 tests in a single day, with multiple other sites exceeding 150 tests in a single day.
As noted by Collection Sites President Tim Shelburn during the QuestCap investor webinar with The NEO Exchange (recording), the company continues to engage with retailers and similar businesses looking to host collection sites at their locations and will make further announcements as they are signed.
To summarize, to date the following agreements have been signed, for a total of up to 743 contracted collection sites:
Brixmor – 340 Retail Locations Brookfield Properties – 73 Shopping Mall Locations H&S Energy, LLC – Up to 100 Gas and Convenience Locations Sandor - 65 Big Boxstore Locations Simons Property Group - 165 Shopping Mall Locations
“Our initial strategy has been that of a land grab, securing convenient, high-traffic locations that will perform exceptionally during the upcoming holiday season and beyond,” commented Tim Shelburn, Collection Site President. “With over 700 sites secured and counting, we believe we have the best footprint in the country for offering convenient and effective COVID-19 testing. With the operational model now proven, our team is laser-focused on the execution fo the rollout of these sites.”
25 New Collection Sites Launched With WillScot Trailers
Starting this week, Collection Sites will rollout 25 portable trailers from WillScot in hand-picked high-traffic locations across the U.S., including states like Texas, Indiana, Pennsylvania, and Florida, among others. WillScot is a international company that sells or leases portable trailers to customers across the United States. After this initial site rollout with WillScot, Collection Sites will look to fulfill its previously announced network of collection sites.
WillScot has a fleet in excess of 360,000 trailers globally and over 140,000 trailers across the United States. These trailers are spread out across the country and can be deployed to a desired site in 2-3 days. The use of WillScot trailers allows Collection Sites to drastically reduce the upfront capital requirements and delivery cost.
These new trailers measure 20’ x 8’ and offer customers and staff reprieve from the outdoor conditions during the winter season, including built-in heating units.
QuestCap Corporate Update Webinar
QuestCap is hosting a Corporate Update webinar on Thursday December 10th at 1 pm ET that will provide investors with an update on the Company's business developments since the last update, with a primary focus on the Collection Sites subsidiary.
Collection Sites COVID-19 testing centers offer convenient access to rapid antibody and antigen tests - which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR, with results within 24 hours of testing. The testing centres are powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. All tests can be administrered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.
For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.
About QuestCap Inc.
QuestCap Inc. (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.
QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.
QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.
For additional information, please contact:
Doug Sommerville, CEO Doug.Sommerville@questcapinc.com +1 416-301-5418
For investing inquiries please contact: Evan Veryard Evan.Veryard@questcapinc.com
For US media enquires please contact: Veronica Welch veronica@vewprmedia.com +1-508-643-8000
Cautionary Note Regarding Forward-looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the results of the Collection Site testing cubes; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
If the company's PR's can be believed, this stock is way undervalued and is flying way under the radar. Here's what their revenue projections seem to add up to...
Toronto, Ontario September 23, 2020 — QuestCap Inc. (“QuestCap”) (CSE:QSC; FRA:34C1) is pleased to announce the signing of 15 lease agreements between its wholly owned subsidiary, Collection Sites, LLC and Orange County, CA based retailer H&S Energy, LLC to begin the roll out a network of ‘pop-up’ COVID-19 testing sites. Over the following months, the intention is to evaluate the remaining 85 eligible H&S locations and to sign additional leases and open collection sites at those H&S service stations across California...
...The collection site pods are 100 square feet and provide three separate and physically distant testing windows to administer 150 tests per testing pod per day and can be placed anywhere with access to electricity. Testing services average USD$60 per test with a capacity for 15 tests per hour, operating 10 hours per day, seven days per week.
That translates to...
15 sites x 150 tests/day x $60/test x 30 days/month = $4,050,000/mo
TORONTO, Oct. 21, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of an agreement between its wholly owned subsidiary, Collection Sites, LLC and Sandor Development Company (“Sandor”), one of the largest privately-held shopping center developers with locations across the United States which often adjoin such retail giants as Home Depot, Walmart, and Target and Kroger, among others. Collection Sites will lease 50 x 100 ft of space in the parking lots of 65 shopping centers owned or managed by Sandor, for an initial 6-month term with the option to extend...
...The first location is set to begin installation in November 2020 with daily testing capacity of 150 tests per site and charging USD $59 to $139 per test.
Let's conservatively assume an average of $75/test...
That translates to...
65 sites x 150 tests/day x $75/test x 30 days/month = $21,934,500/mo
Toronto, Ontario October 26, 2020 — QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of an agreement between its wholly owned subsidiary, Collection Sites, LLC and BPR REIT Services LLC (“Brookfield Properties”), a subsidiary of global real estate company Brookfield Property Partners, listed on the NASDAQ (NASDAQ:BPY). Collection Sites will lease 50 x 100 ft of space, for an initial 4- month term, in the parking lots of 75 shopping malls owned or managed by Brookfield Properties...
...The network of pop-up labs’ will be located across 73 Brookfield Properites’ shopping centers locations in 35 U.S. states, with California, Texas, and Arizona targeted initially. Testing sites will now be available for Americans seeking fast, available, and accurate testing for themselves and their loved ones in the weeks and months ahead.The first location is set to begin installation in November 2020 with daily testing capacity of 150 tests per site and charging USD $59 to $139 per test.
Let's conservatively assume an average of $75/test...
That translates to...
73 sites x 150 tests/day x $75/test x 30 days/month = $24,637,500/mo
Toronto, Ontario November 18, 2020 — QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of a master license agreement between its wholly owned subsidiary, Collection Sites, LLC and Brixmor Property Group (NYSE: BRX), a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers with retailers including T.J. Maxx, Kroger, Wal-Mart, and L.A. Fitness, among others. Collection Sites will lease space in the parking lots of 340 shopping centers owned by Brixmor for an initial 6-month term with the option to extend...
...The network of pop-up labs’ will be located across 340 Brixmor locations in 32 U.S. states with California and Texas targeted initially. Testing sites will now be available for Americans seeking fast, available, and accurate testing for themselves and their loved ones in the weeks and months ahead. The first location is set to begin installation this month with daily testing capacity of 150 tests per site and charging USD $59 to $139 per test.
Let's conservatively assume an average of $75/test...
That translates to...
340 sites x 150 tests/day x $75/test x 30 days/month = $114,750,000/mo
If we assume that they can get all of these up and running within the next two months and that they remain operational for 6 months before the virus peters out...
6 x $165,372,000 = $992,232,000 by 7/1/2021
Is this on the level???? Why isn't everyone buying this up? What am I missing?
I don't know where everyone went on this board. Hope my last post didn't scare them all away. QuestCap is now trading on the Canadian NEO Exchange. I never heard of NEO until I saw it in a QuestCap PR. Their filings can be found at...
Good to know thanks. The CDN ticker QSC shows bids/asks. Like I said, I felt it was a good short at $1 CDN, which is the minimum price to short with my broker. Needed it to break the $1 and it hit it before opening the next day down 28%. Couldn't catch it, needed couple cents higher. Oh well, Good luck with your trades
Investors should be aware that no firm is making a market in this stock on OTC Link. All prices reflect unsolicited customer orders and investors may have a difficult time selling this stock. Click here for more info on Unsolicited Quotes.
Since there's no Market Makers, there's no bid or ask price. It also does not have any share structure info on COPRF. My Quotestream investment tracker shows 34,190,109 shares OS and -$.02 EPS. This stock is an ADR (American Depository Receipt). An American depositary receipt (ADR) is a U.S.bank-issued certificate representing shares in a foreign stock (CSE: QSC) for trade on American stock exchanges. The Canadian company shows the same number of shares OS as COPRF. The company describes itself as ...
QuestCap Inc., formerly Copper One Inc., is a Canada-based investment company. The Company is focused on the acquisition of equity, debt or other securities of publicly traded or private companies or other entities, financing in exchange for pre-determined royalties or distributions and the acquisition of all or part of one or more businesses, portfolios or other assets.
Based on their PR's the company was recently reorganized under new management and seems to have relatively deep pockets for making acquisitions.
Wow I have never seen a pump that lasts 1 year but that is what QSC has paid for. Incredible lol. This is straight from the promo pages disclaimer. "The Article was issued on behalf of a third party, QuestCap Inc. Market Jar Media Inc. expects to receive the following amounts from Native Ads Inc. in the amount of two hundred, ninety-eight thousand, and eight hundred dollars USD for 365 campaign days (252 business days). $298,800 for this pump. That is unheard of. Not sure what to do here now. Was thinking above $1 CDN would be a great short but after reading they're planning a 1 year pump blitz I am not sure.
News 
Market Data 
Discover 
